Protocol | COG ACNS1422 |
---|---|
Cancer Type: | Medulloblastoma |
Fast Facts |
A Phase II Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Age - Patients must be Greater than or Equal to 3 Years and Less than 22 Years of Age at the Time of Enrollment on ACNS1422 Step 0.
Protocol | COG ACNS1723 |
---|---|
Cancer Type: | High-Grade Glioma |
Fast Facts |
A Phase II Study of Dabrafenib (NSC# 763760) with Trametinib (NSC# 763093) after Local Irradiation in Newly-Diagnosed BRAFV600-Mutant High-Grade Glioma (HGG) (IND# 145355)
Patients must be ≥ 3 Years and ≤ 25 Years of Age at the Time of Enrollment on Step 0.
Note: The HGG Pre-Enrollment Eligibility Screening (Step 0) has been paused until further notice.
Protocol | COG ACNS1831 |
---|---|
Cancer Type: | Low-Grade Glioma |
Fast Facts |
A Phase III Randomized Study of Selumetinib (IND # 77782) versus Carboplatin/Vincristine in
Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
Patients must be ≥ 2 Years and ≤ 21 Years at the Time of Enrollment.
Protocol | COG ACNS1833 |
---|---|
Cancer Type: | Low-Grade Glioma |
Fast Facts |
ACNS1833: A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
Patients must be ≥ 2 years and ≤ 21 years of age at the time of enrollment on ACNS1833 Step 0.
Protocol | COG ANBL00B1 |
---|---|
Cancer Type: | Neuroblastoma-Biology |
Fast Facts |
Neuroblastoma Biology Studies
All Newly Diagnosed Patients with Suspected Neuroblastoma, Suspected Ganglioneuroblastoma, or Suspected Ganglioneuroma/Maturing Subtype Seen at COG Institutions are Eligible for this Study.
Protocol | COG ACNS1931 |
---|---|
Cancer Type: | Low Grade Glioma |
Fast Facts |
COG-ACNS1931: A Phase 3 Study of Selumetinib (NSC# 748727, IND# 77782) or Selumetinib in Combination with Vinblastine for non-NF1, non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations
Feasibility Phase - Patients must be ≥ 2 years and ≤ 21 years of age at the time of enrollment.
Efficacy Phase: Patients must be ≥ 2 years and ≤ 25 years of age at the time of enrollment.
All patients > 21 years of age at the time of enrollment must have had initial diagnosis of low-grade glioma by 21 years of age.
Protocol | COG ACNS2021 |
---|---|
Cancer Type: | CNS - Germ Cell |
Fast Facts |
COG ACNS2021
A Phase 2 Trial of Chemotherapy followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor
Patients must be greater than or equal to 3 years and less than 30 years at the time of study enrollment.
Protocol | COG ACNS1821 |
---|---|
Cancer Type: | CNS - DIPG & HGG |
Fast Facts |
COG ACNS1821: A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG)
Patients must be ≥ 12 months and ≤ 21 years of age at the time of enrollment.
Step 1 enrollment is temporarily closed to accrual.
Protocol | COG ACNS2031 |
---|---|
Cancer Type: | Medulloblastoma |
Fast Facts |
COG-ACNS2031: A Phase 3 Study of Sodium Thiosulfate for the Reduction of Cisplatin-Induced Ototoxicity in Children with Average-Risk Medulloblastoma and Reduced Therapy for Children with Medulloblastoma with Low-Risk Features
Age: ≥ 4 years and ≤ 21 years of age at the time of enrollment
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | COG ALTE03N1 |
---|---|
Cancer Type: | Multi-site Cancer Control |
Fast Facts |
Key Adverse Events After Childhood Cancer
Diagnosis of Primary Cancer at Age 21 or Younger, Irrespective of Current Age.
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | COG AHEP1531 |
---|---|
Cancer Type: | PHITT |
Fast Facts |
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Age: Patients must be ≤ 30 Years of Age at the Time of Diagnosis
As of June 30, 2022, AHEP1531 Group D is temporarily closed to accrual.
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | SWOG S1823 |
---|---|
Cancer Type: | Newly Diagnosed Germ Cell Tumors |
Fast Facts |
A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients With Newly Diagnosed Germ Cell Tumors
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | COG AREN03B2 |
---|---|
Cancer Type: | Renal-Biology |
Fast Facts |
Renal Tumors Classification, Biology, and Banking Study
Patients must be < 30 Years Old at the Time of Diagnosis
Protocol | COG AREN1921 |
---|---|
Cancer Type: | Wilms |
Fast Facts |
COG-AREN1921: Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
Patients must be ≤ 30 years old at study enrollment.
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | SWOG S1823 |
---|---|
Cancer Type: | Newly Diagnosed Germ Cell Tumors |
Fast Facts |
A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients With Newly Diagnosed Germ Cell Tumors
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | COG AGCT1531 |
---|---|
Cancer Type: | Germ Cell |
Fast Facts |
A Phase III Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
Age:
Low Risk Stratum (Stage I Ovarian Immature Teratoma and Stage I Malignant GCT (all sites))
Patients must be < 50 Years of Age at Enrollment.
Standard Risk 1
Patient must be < 11 Years of Age at Enrollment.
Standard Risk 2 & AYA-HEARS
Patients must be ≥ 11 and < 25 Years of Age at Enrollment.
Protocol | COG AGCT1532 |
---|---|
Cancer Type: | Germ Cell |
Fast Facts |
Phase III Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
Age ≥ 11 Years and ≤ 45 Years on the Date of Randomization
Protocol | COG ACNS2021 |
---|---|
Cancer Type: | CNS - Germ Cell |
Fast Facts |
COG ACNS2021
A Phase 2 Trial of Chemotherapy followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor
Patients must be greater than or equal to 3 years and less than 30 years at the time of study enrollment.
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | COG ASCT2031 |
---|---|
Cancer Type: | leukemia |
Fast Facts |
COG-ASCT2031: A Multi-Center, Phase 3, Randomized Trial of Matched Unrelated Donor (MUD) versus HLA-Haploidentical Related (Haplo) Myeloablative Hematopoietic Cell Transplantation for Children, Adolescents, and Young Adults (AYA) with Acute Leukemia or Myelodysplastic Syndrome (MDS)
Age: 6 months to <22 years at enrollment
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | Alliance A041501 |
---|---|
Cancer Type: | NEWLY DIAGNOSED PRECURSOR B-CELL ALL |
Fast Facts |
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | COG AALL1621 |
---|---|
Cancer Type: | Relapsed Refractory CD22 B-ALL |
Fast Facts |
A Phase II Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
Patients must be ≥1 Year and < 22 Years of Age at the Time of Enrollment.
AALL1621 has been temporarily closed to accrual as of March 8, 2022, pending an evaluation of patients currently enrolled on this study.
Protocol | COG AALL1631 |
---|---|
Cancer Type: | Ph+ ALL |
Fast Facts |
International Phase III Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
Age: > 1 Year and < 21 Years at ALL Diagnosis
Protocol | COG AALL1731 |
---|---|
Cancer Type: | B-ALL, B-LLy |
Fast Facts |
A Phase III Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)
Patients must be ≥ 365 Days and < 10 Years of Age (B-ALL Patients without DS)
Patients must be ≥ 365 Days and ≤ 31 Years of Age (B-ALL Patients with DS)
Patients must be ≥ 365 Days and ≤ 31 Years of Age (B-LLy Patients with or without DS
Temporary Closure to Accrual as of 12/19/2022
Protocol | COG AALL1732 |
---|---|
Cancer Type: | B-ALL, B-LLy |
Fast Facts |
A Phase III Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518)for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL,Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Patients must be > 365 Days and < 25 Years of Age
Protocol | COG AALL1821 |
---|---|
Cancer Type: | B-ALL |
Fast Facts |
COG AALL1821
A Phase 2 Study of Blinatumomab (NSC# 765986, IND# 125462) in Combination with Nivolumab (NSC# 748726, IND# 125462), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/=1 to <31 Years Old with First Relapse
Temporary Closure to Accrual as of 12/19/2022
Protocol | COG AAML18P1 |
---|---|
Cancer Type: | Chronic Myeloid Leukemia |
Fast Facts |
COG AAML18P1
Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)
Patient must have been diagnosed with CML-CP at less than 18 years of age
Patient mustbe less than 25 years of age at enrollment
Protocol | COG AAML1831 |
---|---|
Cancer Type: | de nova AML |
Fast Facts |
COG-AAML1831: A phase 3 randomized trial for patients with de novo AML comparing standard therapy including gemtuzumab ozogamicin GO to CPX-351 with GO, and the addition of the FLT3 inhibitor gilteritinib for patients with FLT3 mutations
Patients must be less than 22 years of age at the time of study enrollment.
As of June 14th, 2022, Arms C and D (AC, BC, AD, BD) in protocol AAML1831 are temporarily closed to accrual
Protocol | COG APAL2020SC |
---|---|
Cancer Type: | Relapsed Leukemia |
Fast Facts |
COG APAL2020SC
Pediatric Acute Leukemia (PedAL) Screening Trial – Developing New Therapies for Relapsed Leukemias
Patients must be less than 22 years of age at the time of study enrollment.
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | COG ANHL1931 |
---|---|
Cancer Type: | Lymphoma |
Fast Facts |
COG ANHL1931
A Randomized Phase 3 trial of Nivolumab (NSC#748726 IND#125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma
This is an AYA protocol ≥ 2 years
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | COG ALTE2031 |
---|---|
Cancer Type: | multisite |
Fast Facts |
ALTE2031 - StepByStep: A Randomized Trial of a Mobile Health and Social Media Physical Activity Intervention among Adolescent and Young Adult Childhood Cancer Survivors
Patient must be ≥15 years and < 21 years at the time of enrollment.
Protocol | COG AGCT1531 |
---|---|
Cancer Type: | Germ Cell |
Fast Facts |
A Phase III Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
Age:
Low Risk Stratum (Stage I Ovarian Immature Teratoma and Stage I Malignant GCT (all sites))
Patients must be < 50 Years of Age at Enrollment.
Standard Risk 1
Patient must be < 11 Years of Age at Enrollment.
Standard Risk 2 & AYA-HEARS
Patients must be ≥ 11 and < 25 Years of Age at Enrollment.
Protocol | COG APEC14B1 |
---|---|
Cancer Type: | All patients |
Fast Facts |
The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
Subjects must be ≤ 25 Years of Age at Time of Original Diagnosis, except for Patients who are being Screened Specifically for Eligibility onto a COG (or COG Participating NCTN) Therapeutic Study, for whom there is a Higher Upper Age Limit.
Protocol | COG ALTE03N1 |
---|---|
Cancer Type: | Multi-site Cancer Control |
Fast Facts |
Key Adverse Events After Childhood Cancer
Diagnosis of Primary Cancer at Age 21 or Younger, Irrespective of Current Age.
Protocol | COG ALTE05N1 |
---|---|
Cancer Type: | Multisite Long Term Follow-up |
Fast Facts |
Umbrella Long-Term Follow-Up Protocol
Only Available to Patients Already Enrolled on a COG Intervention Protocol.
Protocol | COG APEC1621 – MATCH Protocol SC |
---|---|
Cancer Type: | Screening |
Fast Facts |
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Protocol | COG APEC1621 - MATCH Protocol A |
---|---|
Cancer Type: | Molecular |
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II subprotocol of LOXO-101 (larotrectinib) in patients with tumors harboring actionable NTRK fusions.
Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.
Protocol | COG APEC1621 - MATCH Protocol D |
---|---|
Cancer Type: | Molecular |
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II subprotocol of LY3023414 in Solid Tumors
Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.
Protocol | COG APEC1621 - MATCH Protocol F |
---|---|
Cancer Type: | Molecular |
COG APEC1621F
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II subprotocol of Ensartinib in patients with tumors harboring ALK or ROS1 genomic alterations
Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.
Protocol | COG APEC1621 - MATCH Protocol K |
---|---|
Cancer Type: | Molecular |
APEC1621K - NCI-COG Pediatric Molecular Analysis for Therapy Choice MATCH - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients with Tumors Harboring IDH1 Mutations
Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.
Protocol | COG APEC1621 - MATCH Protocol M |
---|---|
Cancer Type: | Molecular |
APEC1621M: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 subprotocol of Tipifarnib in patients with tumors harboring HRAS genomic alterations
Patients must be ≥ 12 months and ≤ 21 years of age at the time of study enrollment.
Protocol | COG APEC1621 - MATCH Protocol N |
---|---|
Cancer Type: | Molecular |
APEC1621N: NCI-COG Pediatric Molecular Analysis for Therapy Choice (MATCH) – Phase 2 Subprotocol of LOXO-292 in Patients Harboring RET Gene Alterations
Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.
Protocol | COG ACCL21C2 |
---|---|
Cancer Type: | Multi-site Cancer Control |
Fast Facts |
COG-ACCL21C2: Prospective Cohort Study to Evaluate Immunologic Response Following COVID-19 Vaccination in Children, Adolescents and Young Adults with Cancer
≥6 months and ≤37 years of age at time of enrollment
Protocol | COG ANHL2121 |
---|---|
Cancer Type: | LCH |
Fast Facts |
COG-ANHL2121: Phase 2 Study of Tovorafenib (DAY101) in Relapsed and Refractory Langerhans Cell Histiocytosis
Age: 180 days- <22 years (at time of study enrollment).
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | COG ANBL00B1 |
---|---|
Cancer Type: | Neuroblastoma-Biology |
Fast Facts |
Neuroblastoma Biology Studies
All Newly Diagnosed Patients with Suspected Neuroblastoma, Suspected Ganglioneuroblastoma, or Suspected Ganglioneuroma/Maturing Subtype Seen at COG Institutions are Eligible for this Study.
Protocol | COG ANBL1531 |
---|---|
Cancer Type: | High-Risk Neuroblastoma |
Fast Facts |
A Phase III Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
Age - Patient must be ≥ 365 Days and ≤ 30 Years of Age at Diagnosis.
ARM C perm closed
Protocol | COG ANBL1821 |
---|---|
Cancer Type: | Neuroblastoma |
Fast Facts |
A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# 141913) in Children with Relapsed, Refractory or Progressive Neuroblastoma
Patients ≥ 1 year of age at the time of enrollment are eligible for this study.
Temporary Closed to Accrual as of March 06, 2023
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | COG-ARST2031 |
---|---|
Cancer Type: | High Risk Rhabdomyosarcoma (HR-RMS) |
Fast Facts |
COG ARST2031
A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) plus VINO-CPO Maintenance in Patients with High Risk Rhabdomyosarcoma (HR-RMS)
Patients must be ≤ 50 years of age at the time of enrollment.
Protocol | COG AOST2032 |
---|---|
Cancer Type: | Osteosarcoma |
Fast Facts |
COG-AOST2032: A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma
Patients must be < 40 years of age at the time of enrollment.
Protocol | COG ARST2032 |
---|---|
Cancer Type: | Rhabdomyosarcoma |
Fast Facts |
COG- ARST2032: A Prospective Phase 3 Study of Patients with Newly Diagnosed Very Low-risk and Low-risk Fusion Negative Rhabdomyosarcoma
Patients must be ≤ 21 years at the time of enrollment.
Protocol | COG AOST2031 |
---|---|
Cancer Type: | Osteosarcoma |
Fast Facts |
COG AOST2031
A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma
Patients must be < 50 years at the time of enrollment
Please check out the rare protocol list to locate other studies within this disease site.
Cancer clinical trials are research studies for developing better ways of detecting,
treating, and eventually preventing cancer. By taking part in a clinical trial,
you are among the first to receive new research treatments before they are widely
available. Your participation in a clinical trial will influence the future direction
of cancer care.
If you are interested in participating in a clinical trial, consult with your physician.
Please note: clinical trials are not risk free. Patients must explore the options
that are best for their individuals needs with the help of their physician.